Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $120,137.64 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $120,137.64. Following the completion of the transaction, the insider now owns 84,489 shares in the company, valued at approximately $2,571,000.27. This trade represents a 4.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Nur Nicholson also recently made the following trade(s):

• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Trading Down 2.5 %

NASDAQ:APLS opened at $30.00 on Friday. The stock has a market cap of $3.73 billion, a price-to-earnings ratio of -14.78 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The business’s 50-day simple moving average is $32.08 and its 200 day simple moving average is $33.15.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same period in the previous year, the company earned ($1.17) earnings per share. The business’s revenue for the quarter was up 78.3% on a year-over-year basis. As a group, sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on APLS. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Tuesday, December 17th. Scotiabank dropped their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 6th. Oppenheimer cut their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company decreased their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Finally, Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in APLS. State of New Jersey Common Pension Fund D lifted its position in shares of Apellis Pharmaceuticals by 6.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after purchasing an additional 2,820 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Apellis Pharmaceuticals by 42.2% during the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares in the last quarter. Amalgamated Bank lifted its holdings in Apellis Pharmaceuticals by 5.4% during the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after buying an additional 359 shares during the last quarter. Xponance Inc. grew its position in shares of Apellis Pharmaceuticals by 7.6% in the 2nd quarter. Xponance Inc. now owns 13,773 shares of the company’s stock worth $528,000 after acquiring an additional 968 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Apellis Pharmaceuticals in the 2nd quarter valued at approximately $2,350,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).